Latest Peer-Reviewed Study Published in Frontiers in Public Health Highlights Cost-Efficiency and Improved Clinical Outcomes from Using Cognetivity's Proprietary CognICA(TM) Technology, Showing Savings of Over £40 Million Per Year Compared with Traditional Cognitive Assessment Tools…

Collaboration With Highly Rated Healthcare Provider Opens US Healthcare Market for Brain Health for AI Powered CognICA, Enabling Patient Access to Latest Alzheimer's Drugs Vancouver, British Columbia–(Newsfile Corp. – October 11, 2023) – Cognetivity Neurosciences…

Program Designed to Identify Age-Related Brain Health Issues at an Early Stage, Allowing Effective Provision of Coordinated Care Vancouver, British Columbia–(Newsfile Corp. – October 3, 2023) – Cognetivity Neurosciences Ltd. (CSE: CGN) (OTC Pink: CGNSF) (FSE:…

New Approach to Measuring Impact of Counselling to Deliver Next Generation Care to Mental Health Sufferers in North America Vancouver, British Columbia–(Newsfile Corp. – September 21, 2023) – Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE:…

CognICA Chosen as Winner of Best AI Product in Healthcare Award at CogX Festival Vancouver, British Columbia–(Newsfile Corp. – September 13, 2023) – Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or…